文献速递艾滋病与性传播感染细菌感染、耐药与抗菌药物

美国HIV阳性肾移植供受者KSHV风险与疾病

Kaposi Sarcoma-Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该研究在美国3项多中心肾移植研究中检测HIV阳性受者及供者的抗KSHV抗体,发现HIV阳性受者KSHV血清阳性率为40.6%(143/352),供者为25.2%(33/131),HIV阴性供者为7.5%(4/53);仅MSM状态与血清阳性相关。

要点

  • HIV阳性肾移植受者KSHV血清阳性率40.6%,HIV阳性供者25.2%,HIV阴性供者7.5%。
  • 仅MSM状态与KSHV血清阳性相关,受者RR 1.51(95%CI 1.07-2.14),供者RR 2.39(95%CI 1.03-5.53)。

核心结论

  • 美国HIV阳性供受者中KSHV血清阳性率高,尤其MSM人群;KAD罕见且主要归因于受者KSHV再激活或获得而非供者来源。

研究设计与样本

  • 在3项多中心肾移植研究中,用30抗原多重检测法检测HIV阳性受者及HIV阳性/阴性供者的抗KSHV抗体,KSHV血清阳性定义为对≥1种ORF73或K8.1传统抗原反应,用改良Poisson回归分析危险因素,并监测受者移植后抗体变化和KAD。

主要发现

  • KSHV血清阳性率:HIV阳性受者40.6%(143/352),HIV阳性供者25.2%(33/131),HIV阴性供者7.5%(4/53)。
  • 多变量模型中仅MSM状态与KSHV血清阳性相关:受者相对风险1.51(95%CI 1.07-2.14),供者相对风险2.39(95%CI 1.03-5.53)。
  • 移植物KS发生于1例女性HIV D+/R+受者,可能为供者来源;其余KAD发生于男性HIV D-/R+受者,可能为受者KSHV再激活或获得。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Due to high prevalence of Kaposi sarcoma-associated herpesvirus (KSHV) among people with human immunodeficiency virus (HIV), KSHV-associated disease (KAD) may be increased after kidney transplantation from donors with HIV (HIV D+) to recipients with HIV (HIV R+). METHODS: Anti-KSHV antibodies were measured in HIV R+ and donors with and without HIV (HIV D-) using a 30-antigen multiplex assay within 3 multicenter kidney transplantation studies. KSHV seropositivity was defined as reactivity to conventional KSHV antigens (≥1 ORF73 or K8.1); reactivity to expanded 5-antigen and 30-antigen panels were also reported. Risk factors were identified using modified Poisson regression. Recipients were monitored for posttransplant anti-KSHV antibody changes and KAD. RESULTS: KSHV seroprevalence was 40.6% (143/352) among HIV R+, 25.2% (33/131) among HIV D+, and 7.5% (4/53) among HIV D-. In the multivariable model, only men who have sex with men (MSM) status was associated with KSHV seropositivity (relative risk, 1.51 [95% confidence interval {CI}, 1.07-2.14] in recipients and 2.39 [95% CI, 1.03-5.53] in donors). Among 418 HIV R+ (215 HIV D+/R+, 203 HIV D-/R+), there were 5 KAD cases (incidence, 0.63 cases/100 person-years [95% CI, .26-1.52]): 3 skin-only Kaposi sarcoma (KS), 1 multicentric Castleman disease, and 1 allograft KS. The allograft KS occurred in a female HIV D+/R+ and was likely donor derived. Remaining KAD cases occurred in male HIV D-/R+ and were likely recipient KSHV reactivation or acquisition. CONCLUSIONS: In the United States, KSHV seroprevalence in donors and recipients with HIV was high, particularly among MSM. Reassuringly, KSHV-associated disease was rare and primarily attributed to recipient rather than donor-derived KSHV.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Nambiar PH, Liang T, Labo N, et al. Kaposi Sarcoma-Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States. Clin Infect Dis. 2026. PMID: 40324947. doi:10.1093/cid/ciaf229

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。